RecruitingNot ApplicableNCT06865040

Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications


Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

266 participants

Start Date

Jul 31, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Adult (\>18 years)
  • Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route
  • Naïve to long-term inhaled bronchodilator therapy
  • High risk of post-operative pulmonary complications (Pre-operative FEV1 \< 80%)

Exclusion Criteria12

  • Patient refusal
  • Pregnancy
  • Emergency surgery
  • Patient with a physiological status of WHO IV or ASA ≥ IV
  • Asthma
  • Patients treated with long-acting bronchodilators
  • Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \< 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \< 3 months
  • High-grade unresponsive conductive disorders or unstable arrhythmia
  • Thyrotoxicosis, pheochromocytoma
  • Unbalanced diabetes
  • Hypersensitivity to ß-2 mimetics or lactose
  • Current participation in a trial of another drug therapy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFormoterol Fumarate 12 mcg (Foradil Aerolizer)

Administration in the interventional arm of long-acting inhaled ß-2 mimetics: FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7.

OTHERUsual treatment

usual treatment


Locations(1)

CHRU Amiens

Amiens, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06865040


Related Trials